22 States with the Most Tornadoes in the US
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2024
0mins
Should l Buy CB?
Source: Yahoo Finance
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CB
Wall Street analysts forecast CB stock price to rise
17 Analyst Rating
7 Buy
8 Hold
2 Sell
Moderate Buy
Current: 324.600
Low
283.00
Averages
336.88
High
385.00
Current: 324.600
Low
283.00
Averages
336.88
High
385.00
About CB
Chubb Limited is a Switzerland-based holding company. The Company, through its subsidiaries, provides a range of insurance and reinsurance products and services to clients around the world. Its segments include North America Commercial property and casualty (P&C) Insurance, North America Personal P&C Insurance, North America Agricultural Insurance, Overseas General Insurance, Global Reinsurance and Life Insurance. It offers commercial insurance products and service offerings, such as risk management programs, loss control, and engineering and complex claims management. It provides specialized insurance products to areas, such as aviation and energy. It also offers personal lines insurance coverage, including homeowners, automobile, valuables, umbrella liability and recreational marine products. In addition, it supplies personal accident, supplemental health and life insurance to individuals in select countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Alliance Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing research subject safety and data quality through VCT's proprietary subject registry technology, thereby reducing the risk of clinical trial failures and strengthening study integrity.
- Integrated Insurance Solutions: Chubb, as a leading global underwriter of clinical trials, combines its insurance capabilities with VCT's registry technology to provide pharmaceutical and biotechnology companies with additional protection against duplicate enrollment and other protocol violations during trials.
- Industry Impact Enhancement: This collaboration not only offers stronger protocol compliance and data integrity assurances for research sites and Contract Research Organizations (CROs) but also improves overall clinical trial execution by mitigating preventable risks.
- Proactive Risk Management: The partnership between VCT and Chubb signifies a shift in clinical research risk management from reactive measures to proactive safeguards, aiming to deliver safer and more effective drugs and therapies, thus advancing the entire clinical research ecosystem.
See More
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Partnership Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing research subject safety and data quality by integrating VCT's clinical trial subject registry technology with Chubb's insurance capabilities, thereby improving overall clinical trial success rates.
- Innovative Risk Management: As a leading global underwriter of clinical trials, Chubb will provide tailored insurance solutions for life sciences companies, helping clients manage risks associated with adverse events and protocol deviations, ensuring data integrity and reducing the likelihood of study failures.
- Technological Integration Benefits: This collaboration combines VCT's real-time subject verification capabilities with Chubb's global risk management expertise, shifting clinical research from reactive responses to proactive safeguards, enhancing transparency and reliability in research, ultimately benefiting patients.
- Far-reaching Industry Impact: The alliance not only provides additional protection for sponsors, Contract Research Organizations (CROs), and research sites but also underscores the importance of collaboration between insurers and clinical trial technology leaders in improving clinical research outcomes globally.
See More
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Alliance Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing clinical trial safety and data quality through VCT's proprietary subject registry technology, thereby reducing the risk of trial failures and improving research efficacy.
- Safety Enhancement: This alliance will help mitigate the risk of duplicate or overlapping study participation, reducing adverse events and drug interactions, which ensures the safety of research subjects and ultimately increases the overall success rate of clinical trials.
- Data Quality Improvement: By providing cleaner, more reliable study data, the partnership supports stronger analysis and decision-making capabilities, ensuring compliance with regulatory requirements, thus enhancing the integrity and effectiveness of research.
- Innovative Risk Management: By combining Chubb's insurance capabilities with VCT's registry technology, both parties are committed to reducing preventable operational, financial, and compliance risks, promoting proactive advancements in clinical research that ultimately benefit patients.
See More
Buffett Reduces Apple Stake, Increases Chubb Holdings
- Apple Stake Reduction: Buffett sold approximately 75% of Berkshire Hathaway's Apple stake from early 2024 through his retirement, while still holding a $61.6 billion investment, aiming to rebalance the portfolio, avoid higher corporate taxes, and raise cash for safer short-term U.S. Treasuries.
- Chubb Investment Increase: Following the reduction in Apple, Buffett initiated a position in Chubb in Q3 2023 and continued to accumulate shares through 2025, resulting in an $11.2 billion stake, making it Berkshire's eighth-largest holding, reflecting his affinity for the insurance sector.
- Strategic Shift: Buffett's moves indicate a more defensive investment strategy in the current volatile market, suggesting that
See More
Buffett Reduces Apple Stake While Increasing Chubb Holdings
- Apple Stake Reduction: From early 2024 until his retirement, Buffett sold about three-quarters of Berkshire Hathaway's Apple stake, yet still retains a $61.6 billion investment, indicating a strategic portfolio rebalancing.
- Increased Chubb Holdings: Following the reduction in Apple, Buffett initiated and expanded his position in Chubb, accumulating an $11.2 billion stake by 2025, making it Berkshire's eighth-largest holding, reflecting his ongoing preference for the insurance sector.
- Investment Strategy Shift: The reasons behind Buffett's Apple sales include avoiding higher corporate taxes and raising cash for safer, higher-yielding short-term U.S. Treasuries, suggesting a more defensive investment approach in the current volatile market.
- Market Outlook: While Buffett is not bearish on Apple, his portfolio adjustments imply that
See More
Buffett's Investment Style Continues at Berkshire Hathaway
- Domino's Pizza Rebound: Berkshire Hathaway's 10% stake in Domino's Pizza is currently trading at a P/E ratio of 21, down 34.5% from its highs, indicating significant growth potential in the global fast-food market, particularly due to its competitive pricing advantage.
- Chubb Insurance Investment: Berkshire holds approximately 8.8% of Chubb, valued at over $11 billion, which has delivered a remarkable 5,440% cumulative return to shareholders over the past 30 years, showcasing its strong performance and profitability in the insurance sector.
- American Express Market Leadership: As a major investment for Berkshire, American Express leads the premium credit card market, acquiring 2.9 million net new cards in Q4 2025, with a 9% revenue increase to $72 billion, reflecting its strong customer appeal and profitability.
- Stock Buyback Strategy: Both Domino's and American Express consistently repurchase shares, with Domino's reducing its outstanding shares by 27.8%, which not only enhances earnings per share but also aligns with Buffett's investment philosophy emphasizing long-term value creation.
See More
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Alliance Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing research subject safety and data quality through VCT's proprietary subject registry technology, thereby reducing the risk of clinical trial failures and strengthening study integrity.
- Integrated Insurance Solutions: Chubb, as a leading global underwriter of clinical trials, combines its insurance capabilities with VCT's registry technology to provide pharmaceutical and biotechnology companies with additional protection against duplicate enrollment and other protocol violations during trials.
- Industry Impact Enhancement: This collaboration not only offers stronger protocol compliance and data integrity assurances for research sites and Contract Research Organizations (CROs) but also improves overall clinical trial execution by mitigating preventable risks.
- Proactive Risk Management: The partnership between VCT and Chubb signifies a shift in clinical research risk management from reactive measures to proactive safeguards, aiming to deliver safer and more effective drugs and therapies, thus advancing the entire clinical research ecosystem.
See More
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Partnership Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing research subject safety and data quality by integrating VCT's clinical trial subject registry technology with Chubb's insurance capabilities, thereby improving overall clinical trial success rates.
- Innovative Risk Management: As a leading global underwriter of clinical trials, Chubb will provide tailored insurance solutions for life sciences companies, helping clients manage risks associated with adverse events and protocol deviations, ensuring data integrity and reducing the likelihood of study failures.
- Technological Integration Benefits: This collaboration combines VCT's real-time subject verification capabilities with Chubb's global risk management expertise, shifting clinical research from reactive responses to proactive safeguards, enhancing transparency and reliability in research, ultimately benefiting patients.
- Far-reaching Industry Impact: The alliance not only provides additional protection for sponsors, Contract Research Organizations (CROs), and research sites but also underscores the importance of collaboration between insurers and clinical trial technology leaders in improving clinical research outcomes globally.
See More
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Alliance Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing clinical trial safety and data quality through VCT's proprietary subject registry technology, thereby reducing the risk of trial failures and improving research efficacy.
- Safety Enhancement: This alliance will help mitigate the risk of duplicate or overlapping study participation, reducing adverse events and drug interactions, which ensures the safety of research subjects and ultimately increases the overall success rate of clinical trials.
- Data Quality Improvement: By providing cleaner, more reliable study data, the partnership supports stronger analysis and decision-making capabilities, ensuring compliance with regulatory requirements, thus enhancing the integrity and effectiveness of research.
- Innovative Risk Management: By combining Chubb's insurance capabilities with VCT's registry technology, both parties are committed to reducing preventable operational, financial, and compliance risks, promoting proactive advancements in clinical research that ultimately benefit patients.
See More
Buffett Reduces Apple Stake, Increases Chubb Holdings
- Apple Stake Reduction: Buffett sold approximately 75% of Berkshire Hathaway's Apple stake from early 2024 through his retirement, while still holding a $61.6 billion investment, aiming to rebalance the portfolio, avoid higher corporate taxes, and raise cash for safer short-term U.S. Treasuries.
- Chubb Investment Increase: Following the reduction in Apple, Buffett initiated a position in Chubb in Q3 2023 and continued to accumulate shares through 2025, resulting in an $11.2 billion stake, making it Berkshire's eighth-largest holding, reflecting his affinity for the insurance sector.
- Strategic Shift: Buffett's moves indicate a more defensive investment strategy in the current volatile market, suggesting that
See More
Buffett Reduces Apple Stake While Increasing Chubb Holdings
- Apple Stake Reduction: From early 2024 until his retirement, Buffett sold about three-quarters of Berkshire Hathaway's Apple stake, yet still retains a $61.6 billion investment, indicating a strategic portfolio rebalancing.
- Increased Chubb Holdings: Following the reduction in Apple, Buffett initiated and expanded his position in Chubb, accumulating an $11.2 billion stake by 2025, making it Berkshire's eighth-largest holding, reflecting his ongoing preference for the insurance sector.
- Investment Strategy Shift: The reasons behind Buffett's Apple sales include avoiding higher corporate taxes and raising cash for safer, higher-yielding short-term U.S. Treasuries, suggesting a more defensive investment approach in the current volatile market.
- Market Outlook: While Buffett is not bearish on Apple, his portfolio adjustments imply that
See More
Buffett's Investment Style Continues at Berkshire Hathaway
- Domino's Pizza Rebound: Berkshire Hathaway's 10% stake in Domino's Pizza is currently trading at a P/E ratio of 21, down 34.5% from its highs, indicating significant growth potential in the global fast-food market, particularly due to its competitive pricing advantage.
- Chubb Insurance Investment: Berkshire holds approximately 8.8% of Chubb, valued at over $11 billion, which has delivered a remarkable 5,440% cumulative return to shareholders over the past 30 years, showcasing its strong performance and profitability in the insurance sector.
- American Express Market Leadership: As a major investment for Berkshire, American Express leads the premium credit card market, acquiring 2.9 million net new cards in Q4 2025, with a 9% revenue increase to $72 billion, reflecting its strong customer appeal and profitability.
- Stock Buyback Strategy: Both Domino's and American Express consistently repurchase shares, with Domino's reducing its outstanding shares by 27.8%, which not only enhances earnings per share but also aligns with Buffett's investment philosophy emphasizing long-term value creation.
See More
